The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist

@inproceedings{Bain2014TheCD,
  title={The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist},
  author={Stephen C Bain},
  booktitle={Diabetes therapy : research, treatment and education of diabetes and related disorders},
  year={2014}
}
Lixisenatide (AVE0010) is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes. Phase II dose-finding and pharmacodynamic studies identified the 20 µg once-daily dose as having the optimum combination of efficacy, convenience and tolerability. Lixisenatide was prospectively investigated in a series of 11 multinational, randomised, controlled phase III trials (GLP-1 agonist AVE0010 in paTients with type 2 diabetes mellitus for Glycemic cOntrol… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

Long-term safety of once-daily (QD) lixisenatide in Japanese patients with type 2 diabetes (T2DM): GetGoalMono Japan

  • Y Seino, T Akane, E Niemoller
  • J Diabetes Investig. ;3(Suppl
  • 2012
Highly Influential
9 Excerpts

Similar Papers

Loading similar papers…